Join
Live feed
·
PRReleasevia Quantisnow
Alterity Therapeutics Limited logo

Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders

ByQuantisnow·Wall Street's wire, on your screen.
ATHE· Alterity Therapeutics Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ATHE (Alterity Therapeutics Limited) and more on Quantisnow.